[The efficacy of G-CSF and GM-CSF in the adjunctive treatment of infections complicating chemotherapy of solid tumors in children. Report of Polish Pediatric Leukemia/Lymphoma Treatment Group].
Total number of 306 cycles of GM-CSF-Leucomax Sandoz (5 mg/kg/day s.c.) and/or G-CSF Filgrastim Hoffmann-La Roche (5-10 mg/kg/day s.c.) was applied in 146 children aged from 0.5-18 years during neutropenia associated with chemotherapy of solid tumours. Seventeen children with malignancies served as a historical control group. Our study have demonstrated after both G- and GM-CSF therapy shorter period of neutropenia, reduction of the number of febrile days and a decreased frequency of infectious complications and infection's duration.
Chybicka
A
A
Kliniki Hematologii i Chorób Rozrostowych Dzieci Akademii Medycznej we Wrocławiu.
Bogusławska-Jaworska
J
J
Rosińska
B
B
Wecławek-Tompol
J
J
Armata
J
J
Balcerska
A
A
Balwierz
W
W
Bubała
H
H
Drabko
K
K
Eliasińska
A
A
Kedziora
M
M
Kołecki
P
P
Kowalczyk
J
J
Matysiak
M
M
Płoszyńska
A
A
Rokicka-Milewska
R
R
Sońta-Jakimczyk
D
D
Sopyło
B
B
Stefaniak
M J
MJ
Stańczak
E
E
Stencel
D
D
Wysocki
M
M
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007239:Infections / Q000150:complications* / Q000188:drug therapy*; D007938:Leukemia / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D009503:Neutropenia / Q000150:complications*; D011044:Poland; D015996:Survival Rate; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor